Clover Health Investments, Corp. (NASDAQ:CLOV) Short Interest Up 9.0% in January

Clover Health Investments, Corp. (NASDAQ:CLOV - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 15,960,000 shares, an increase of 9.0% from the December 31st total of 14,640,000 shares. Based on an average daily trading volume, of 6,180,000 shares, the short-interest ratio is presently 2.6 days.

Institutional Investors Weigh In On Clover Health Investments

Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in Clover Health Investments by 21.9% during the 3rd quarter. Geode Capital Management LLC now owns 4,828,701 shares of the company's stock worth $13,622,000 after purchasing an additional 868,501 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Clover Health Investments by 5.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,000,505 shares of the company's stock valued at $8,461,000 after buying an additional 150,550 shares during the period. State Street Corp increased its position in shares of Clover Health Investments by 65.0% during the third quarter. State Street Corp now owns 2,189,380 shares of the company's stock worth $6,174,000 after acquiring an additional 862,621 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Clover Health Investments by 75.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,128,171 shares of the company's stock worth $3,181,000 after acquiring an additional 485,987 shares during the period. Finally, AQR Capital Management LLC lifted its position in Clover Health Investments by 4.6% in the 2nd quarter. AQR Capital Management LLC now owns 729,706 shares of the company's stock valued at $898,000 after acquiring an additional 32,288 shares in the last quarter. Institutional investors and hedge funds own 19.77% of the company's stock.

Clover Health Investments Stock Up 3.7 %

NASDAQ CLOV traded up $0.16 during trading on Tuesday, reaching $4.47. 7,268,906 shares of the stock traded hands, compared to its average volume of 6,978,224. The stock's 50-day moving average price is $3.62 and its 200 day moving average price is $3.25. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of -22.35 and a beta of 1.98. Clover Health Investments has a fifty-two week low of $0.61 and a fifty-two week high of $4.87.

Clover Health Investments (NASDAQ:CLOV - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. The company had revenue of $330.99 million during the quarter, compared to analyst estimates of $347.60 million. Clover Health Investments had a negative net margin of 5.92% and a negative return on equity of 25.46%. During the same quarter in the previous year, the business earned ($0.09) EPS. Analysts anticipate that Clover Health Investments will post -0.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Craig Hallum started coverage on Clover Health Investments in a research note on Tuesday, December 17th. They issued a "buy" rating and a $6.00 price target on the stock. UBS Group initiated coverage on Clover Health Investments in a research note on Monday, October 7th. They issued a "neutral" rating and a $4.00 target price on the stock.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.